Skip to main navigation
Avadel Pharmaceuticals
  • Recent News
  • Investors
  • About
    • Overview
    • Leadership
    • Board of Directors
    • Business Development
    • Corporate Responsibility
  • Research
    • Clinical Trials
  • Contact Us
  • Call Today
  • Email Us
  • Our Map
    • Avadel Pharmaceuticals
    • 636.449.1830
    • Home
    • About
      • Overview
      • Leadership
      • Board of Directors
      • Business Development
      • Corporate Responsibility
    • Research Pipeline
      • Clinical Trials
    • Investor Relations

      • Investors
      • News & Events
        • Press Releases
        • Events
        • Presentations
      • Stock Information
        • Stock Quote & Chart
        • Historical Price Lookup
        • Investment Calculator
        • Analyst Coverage
      • Financial Information
        • SEC Filings
        • Financial Reports
        • Quarterly Results
      • Corporate Governance
        • Governance Highlights
        • Management Team
        • Board of Directors
        • Committee Composition
        • Annual General Meeting
      • Shareholder Services
        • Investor FAQs
        • Information Request
        • E-mail Alerts
        • IR Contacts
    • Contact Us
646.449.1830

Breadcrumb

  1. Home
  2. Investors
  3. Press Releases
  4. Avadel Pharmaceuticals to Report Second Quarter 2019 Financial Results

Press Releases

Printer Friendly Version View printer-friendly version << Back
July 29, 2019 at 7:00 AM EDT

Avadel Pharmaceuticals to Report Second Quarter 2019 Financial Results

PDF Version

DUBLIN, Ireland, July 29, 2019 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218 for narcolepsy, today announced that it will host a conference call and live webcast discussion at 8:30 a.m. EDT on Friday, August 9, 2019, to provide a corporate update and discuss the Company's financial results for the second quarter ended June 30, 2019.

To access the conference call, investors are invited to dial (844) 388-0559 (U.S. and Canada) or (216) 562-0393 (international). The conference ID number is 4290467. A live audio webcast can be accessed by visiting the investor relations section of the Company’s website, www.avadel.com. A replay of the webcast will be archived on Avadel’s website for 90 days following the event.

About Avadel Pharmaceuticals plc:

Avadel Pharmaceuticals plc (Nasdaq: AVDL) is a branded specialty pharmaceutical company.  The Company’s primary focus is on the development and potential FDA approval for FT218, which is in a Phase 3 clinical trial for the treatment of narcolepsy patients suffering from excessive daytime sleepiness (EDS) and cataplexy. In addition, Avadel develops and markets a portfolio of sterile injectable drugs used in the hospital setting. For more information, please visit www.avadel.com.

Contacts: Michael F. Kanan
  Chief Financial Officer
  Phone: (636) 449-1844
  Email: mkanan@avadel.com
   
  Lee Roth
  Burns McClellan
  Phone: (212) 213-0006
  Email: lroth@burnsmc.com

AVDL Pharma TM.PNG

Source: Avadel Pharmaceuticals plc

Tools

  • Print Page
  • RSS
  • E-mail Alerts

Investor Relations

  • Investors
  • News & Events
    • Press Releases
    • Events
    • Presentations
  • Stock Information
    • Stock Quote & Chart
    • Historical Price Lookup
    • Investment Calculator
    • Analyst Coverage
  • Financial Information
    • SEC Filings
    • Financial Reports
    • Quarterly Results
  • Corporate Governance
    • Governance Highlights
    • Management Team
    • Board of Directors
    • Committee Composition
    • Annual General Meeting
  • Shareholder Services
    • Investor FAQs
    • Information Request
    • E-mail Alerts
    • IR Contacts

Contact Avadel Pharmaceuticals Today

Avadel Pharmaceuticals

Helpful Links Site Map | Privacy Policy | Terms and Conditions

  • Overview
  • News & Events
  • Careers
  • Investors
  • Contact Us
16640 Chesterfield Grove Road,
Suite 200,
Saint Louis, MO 63005 |  View Map [+]
http://www.avadel.com/
Site Map | Privacy Policy
http://www.avadel.com/

© COPYRIGHT AVADEL PHARMACEUTICALS, PLC. ALL RIGHTS RESERVED

0117 AVL WBST MAIN_KP2